Gastric pentadecapeptide BPC 157, now found to be effective in the upper and lower GI tract, is remarkably free of side effects, as are the other peptides being used in functional medicine
Cardiovascular disease, hypertension, and dyslipidaemia (frequently present in patients prescribed GLP-1 agents) all impair the vascular mechanisms essential for achieving and maintaining erections
The sensitivity analysis seen in Figure 4, including the phase III studies only, provided a similar result with a mean difference in SBP of 4.83 mmHg (95% CI: 5.72 to 3.94)
There is ongoing research into the role of GLP-1 agonists in managing gestational diabetes, particularly for women who were on these medications prior to pregnancy
In addition, black patients had the lowest odds of prescription compared with white patients adjusted OR = 0.72 (95% CI, 0.71-0.74) for SGLT2 inhibitors and 0.64 (95% CI, 0.63-0.66) for GLP-1 receptor agonists while Hispanic or Latino patients had lower odds of prescription compared with non-Hispanic or non-Latino patients aOR = 0.9 (95% CI, 0.88-0.93) for SGLT2 inhibitors and 0.88 (95% CI, 0.85-0.91) for GLP-1 receptor agonists
